What's in Vyne Therapeutics Inc.'s pipeline?

Vyne Therapeutics Inc. has 16 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 7 in Phase 2, 3 in Phase 1.

Which companies overlap with Vyne Therapeutics Inc.'s portfolio?

Top competitors by shared drug class: Air Force Specialized Hospital, Cairo, Egypt, Beijing Tiantan Hospital, Chinese University of Hong Kong, Clinica Universidad de Navarra, Universidad de Navarra, Darier.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/vyne-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Vyne Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vyne Therapeutics Inc. pipeline: 1 marketed, 0 filed, 5 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 7 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Vehicle Foam	Vehicle Foam	marketed			Dermatology
FMX-101, 4% minocycline foam	FMX-101, 4% minocycline foam	phase 3	Tetracycline antibiotic	Bacterial ribosome (30S subunit); also has anti-inflammatory effects on host immune cells	Dermatology
FMX101	FMX101	phase 3	Topical tetracycline antibiotic	Bacterial ribosome (30S subunit); inflammatory mediators	Dermatology
FMX103 minocycline foam 1.5%	FMX103 minocycline foam 1.5%	phase 3	Tetracycline antibiotic	Bacterial ribosome (30S subunit); also has anti-inflammatory effects on host immune mediators	Dermatology
FMX103 1.5%	FMX103 1.5%	phase 3	Topical antibiotic with anti-inflammatory properties	Bacterial protein synthesis (30S ribosomal subunit); inflammatory mediators	Dermatology
Matching Placebo Tablets	Matching Placebo Tablets	phase 3

Therapeutic area mix

Dermatology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Air Force Specialized Hospital, Cairo, Egypt · 1 shared drug class
Beijing Tiantan Hospital · 1 shared drug class
Chinese University of Hong Kong · 1 shared drug class
Clinica Universidad de Navarra, Universidad de Navarra · 1 shared drug class
Darier · 1 shared drug class
Edward Lain, MD · 1 shared drug class
Galderma R&D · 1 shared drug class
ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vyne Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Vyne Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vyne-therapeutics-inc. Accessed 2026-05-17.